Iron Balance Study of DFO and GT56-252 in Patients With Transfusional Iron Overload Secondary to Beta-Thalassemia

NCT00069862 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

25

Enrollment

INDUSTRY

Sponsor class

Conditions

Beta-Thalassemia

Interventions

DRUG: Deferitrin (GT56-252)
DRUG: desferoxamine (DFO)

Sponsor

Genzyme, a Sanofi Company